ADVERTISEMENT

ICICI Direct: Dr. Reddy’s Revlimid Settlement A Significant U.S. Opportunity

Dr. Reddy’s is the third player after Natco Pharma and Alvogen to sign a settlement agreement with Celgene for gRevlimid.

Security guards work in the lobby of the Innovation Plaza building, on the Dr. Reddy’s Laboratories Ltd. campus in Hyderabad, India. (Photographer: Prashanth Vishwanathan/Bloomberg)
Security guards work in the lobby of the Innovation Plaza building, on the Dr. Reddy’s Laboratories Ltd. campus in Hyderabad, India. (Photographer: Prashanth Vishwanathan/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Dr. Reddy’s Laboratories Ltd. has announced the settlement of its Revlimid capsules (Lenalidomide) patent litigation with Celgene (subsidary of Bristol Myers Squibb) in the U.S.

This makes Dr. Reddy’s the third player after Natco Pharma Ltd. and Alvogen to sign a settlement agreement with the innovator for gRevlimid.

Under the terms of the settlement, Celgene will provide Dr. Reddys with a license to sell generic volume-limited amounts of gRevlimid capsules in the U.S. after Natco’s launch in March 2022 subject to regulatory approval.

This limited volume constraint will be applicable till January 31, 2026, post which Dr. Reddy’s will be able to sell the drug in the U.S. without any volume limitations whatsoever.

The oncology drug, indicated for treatment of multiple myeloma, had annual U.S. sales of 9 billion U.S. dollar in CY19 as per BMS report.

Click on the attachment to read the full report:

ICICI Direct Dr Reddy Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.